KeyBanc Sees Hims & Hers Facing a Transition Year in 2026
KeyBanc analyst Justin Patterson said 2026 could be a transition year for Hims & Hers as it invests in AI, new treatments and international expansion. The headline also says lower pricing is expected to weigh on its FY2027–2028 earnings outlook.